Member Info for EmeraldCarrots

I think they are.

This one:-

https://www.voxmarkets.co.uk/articles/angle-plc-trinity-delta-b14b59c/

Down 5.85% now.

Same again I wonder?

Hope so.

Just as likely to re-visit 31p (Jan 3rd this year) IMHO on another houseold name coming on board.

- Sp seems to have support around the 20p level for now...... Excellent!!!

While you and the likes of TwoGood2Die have said next to nothing positive about Angle Plc during that period. How does that make you feel? Must be quite frustrating to think an investment of £1,000 just last Nov is now worth over £2,000. On 21st November 2023 I bought £1,499's worth @0.101. Just missed the sub 10p by a whisker, but I won't be crying about that. They are now worth £3,075.00. I bought more @ 12p and 15p. A lot, lot more.

I suggest you filter me and stop complaining about posters all the time. Looking back at your posts most of them are complaining about posts by various people. Hardly any meaningful information at all.

Get a life!

All IMHO.

Picathartes.

"Excellent post Mr Carrot".

============================

Thanks.

There are 48 Pharma Co's in the World that have larger market caps than Eisai Inc. (15 billion $). In view of that it seems probable that Angle Plc are going to get a lot more orders to analyse the circulating tumour cells their Parsortix machine can catch, 99% of them live, ideal for testing. One would have thought they will be inundated with enquiries? Time will tell.

All IMHO.

Rong53.

"99k trade , that's probably the reason the SP has gone blue"

============

Where do you get the 99K from. Is that shares or £?

So explain that one.

Don't tell me. More buys that sells eh?? Heard that one before!

More likely the mm's have been down the pub. LOL!

Ticked up again.

Ticked up.

Of a snowballing demand for Angle's services analysing circulating tumour cells.

Agreements this year:-

1. 2nd January. Eisai Inc. (15 Billion $ market cap). Announcement was regarding the ***HER2 protein***.

Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. Success in the pilot study offers the potential for multiple large scale follow-up studies.

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

2. 24th April. Astrazeneca Plc ($211 billion market cap). Announcement was regarding micronuclei detection based on its existing pKAP1 CTC-based DDR assay.

Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html

3. 3rd May. Astrazeneca Plc ($211 billion market cap). Announcement was to develop an Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.

Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

The above announcements are fantastically good for Angle. However, if the market can also see demand for the announcement of the 4th Jan the sp will truly take off IMHO.

This was regarding the Combined DNA Next Generation Sequencing of CTCs and CtDna from the same blood sample test.

It compares the CtDna (DNA fragments found in the general blood) with the DNA of the circulating cancer cells the Parsortix machine can catch.

Angle have found unexpected variations between the two indicating CtDna analysis alone sometimes misses vital information.

This test can be used in ***ANY cancer drug trial involving ANY type of cancer which has metastasised***.

I believe it may become a part of the ***standard analysis*** during cancer drug trials involving metastasised cancer

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.ht

Of a snowballing demand for Angle's services analysing circulating tumour cells.

Big agreements this year:-

1. 2nd January. Eisai Inc. (15 Billion $ market cap). Announcement was regarding the ***HER2 protein***.

Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. Success in the pilot study offers the potential for multiple large scale follow-up studies.

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

2. 24th April. Astrazeneca Plc ($211 billion market cap). Announcement was regarding micronuclei detection based on its existing pKAP1 CTC-based DDR assay.

Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html

3. 3rd May. Astrazeneca Plc ($211 billion market cap). Announcement was to develop an Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.

Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

The above announcements are fantastically good for Angle. However, if the market can also see demand for the announcement of the 4th Jan the sp will truly take off IMHO.

This was regarding the Combined DNA Next Generation Sequencing of CTCs and CtDna from the same blood sample test.

It compares the CtDna (DNA fragments found in the general blood) with the DNA of the circulating cancer cells the Parsortix machine can catch.

Angle have found unexpected variations between the two indicating CtDna analysis alone sometimes misses vital information.

This test can be used in ***ANY cancer drug trial involving ANY type of cancer which has metastasised***, and clearly gives additional important information.

I believe it may become a part of the ***standard analysis*** during cancer drug trials involving metastasised cancer.

All IMHO.

And do the opposite?

Who knows what next week may bring!

https://www.proactiveinvestors.co.uk/companies/news/1046802/angle-announces-second-assay-with-astrazeneca-as-it-deepens-relationship-with-pharma-giant-1046802.html

The bidder for Wood Group will look at Petrofac. They would be mad not to. I think Petrofac will get taken over.

USA players??

Ah, no. It's probably Illumina building a stake. LOL! No...... Astrazeneca. No No... its probably Eisai. No No No. What about Thermo Fisher?? LOL!!!

Maybe all of them !!!

Who knows??????????????

LOL! All IMHO.

Someone saw that too! Ticked up. Asl now 22p. 80,000 trade as well.

Likely.

Oppertunity to do the same at a similar price. I wonder.....

And Eisai contracts have caught more players attention, obviously. I mean back last Nov we could have less than 15 trades all day!!! 265 now.